Fatal Microangiopathic Hemolytic Anemia Due to Sézary Syndrome
Open Access
- 6 June 2021
- journal article
- research article
- Published by Springer Nature in Cureus
- Vol. 13 (6) , e15482
Abstract
Sézary syndrome (SS) is a form of cutaneous T-cell lymphoma (CTCL), demonstrating leukemic involvement of malignant T-cells. Known systemic sequelae of SS include hemophagocytic syndrome-induced anemia, normocytic anemia secondary to bone marrow infiltration, and pancytopenia. We report a patient with SS, initially demonstrating widespread morbilliform eruption, who presented with malignancy-related microangiopathic hemolytic anemia (MAHA). Our findings represent a novel presentation of SS that will inform the differential diagnosis and treatment of future SS patients presenting with anemia and thrombocytopenia.Keywords
This publication has 16 references indexed in Scilit:
- Cancer-associated thrombotic microangiopathyecancermedicalscience, 2016
- Microangiopathic Hemolytic Anemia and Thrombocytopenia in Patients With CancerJournal of Oncology Practice, 2016
- Microangiopathic hemolytic anemia associated with metastatic breast cancer: case report and literature reviewSpringerPlus, 2016
- ADAMTS-13 in the Diagnosis and Management of Thrombotic MicroangiopathiesRambam Maimonides Medical Journal, 2014
- Systemic malignancies as a cause of unexpected microangiopathic hemolytic anemia and thrombocytopenia.2011
- Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 casesBlood, 2009
- Bone Marrow Histopathologic and Molecular Staging in Epidermotropic T-Cell LymphomasAmerican Journal of Clinical Pathology, 2003
- Autoimmune Hemolytic Anemia Presenting in Sézary SyndromeActa Haematologica, 1992
- Sezary syndrome in a patient with hairy cell leukemia in remissionCancer, 1991
- Sézary syndrome: Diagnosis, prognosis, and critical review of treatment optionsJournal of the American Academy of Dermatology, 1990